



For immediate release

Aciont's Research Discussed in Two Recent Ophthalmic Publications

Salt Lake City, UT - The Investigative Ophthalmology & Visual Science journal published an article summarizing the presentations at the Third Annual ARVO Pfizer Ophthalmics Research Institute Conference; the article was called, "[Drug Delivery to Posterior Intraocular Tissues](#)." The conference attendees, a diverse group of experts in ocular drug delivery, evaluated current and innovative techniques to deliver therapeutic drug levels to intraocular tissues in the posterior segment of the eye.

The article included information about a presentation from Dr. Kevin Li on transscleral ocular drug delivery. Li's presentation discussed various approaches to transscleral drug delivery research by Aciont[®] including iontophoresis, sustained release iontophoresis, and passive diffusion of compounds, such as triamcinolone acetonide phosphate, to the posterior section of the eye. Li's presentation included results from Aciont's pharmacokinetic and efficacy studies which demonstrated the therapeutic merits of delivering a sustained release depot to the eye from a non-invasive application.

A separate article, entitled "Passive and Oxymetazoline-Enhanced Delivery with a Lens Device: Pharmacokinetics and Efficacy Studies with Rabbits," published in the [Journal of Ocular Pharmacology and Therapeutics](#), presented results from studies completed through a phase I NIH/NEI SBIR grant. The study suggests that topical delivery of a pharmaceutical drug formulation using Aciont's Visulex[®] ocular application device could be effective in treating non-infectious, severe uveitis.

About Aciont[®]

Aciont[®] Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont's goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont[®] is located in Salt Lake City, Utah. For more information, visit the company's website at www.aciont.com.

Source: Aciont[®] Inc.

Contact

John Higuchi
President
Aciont[®] Inc.
(801) 359-3461